TSC2 and neoplasm: Recently a dual pan class I PI3K/mTOR catalytic small molecule inhibitor NVP-BEZ-235 used to treat TSC2-deficient kidney tumors did not induce the increase in phospho-AKT (S473) levels observed with RAD001 [53], although both drugs were equally effective in suppressing tumor growth.